Skip to content
Austin Top 50
Author:
Latigo Biotherapeutics, Inc
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
September 3, 2026
Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
August 6, 2026